$6.87
+2.6%Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.
Wall Street analysts project that ARTV stock may rise significantly over the coming 12 months. The consensus 1-year price target stands at 37.50, with estimates ranging from a low of 35.00 to a high of 40.00.
The consensus 1-year price target stands at 37.50, with estimates ranging from a low of 35.00 to a high of 40.00.
Substantial upside potential. Analysts see significant value gap, suggesting the stock may be materially undervalued at current levels.
High analyst agreement. Narrow target range indicates strong consensus on valuation, suggesting clear investment thesis and predictable outlook.
Strong buy conviction: High upside with tight consensus suggests compelling investment opportunity backed by analyst confidence.
Rare opportunity: Exceptional upside potential with strong analyst consensus creates a compelling setup. The combination of significant price target premium and tight agreement suggests high-conviction undervaluation that may attract institutional capital.
Moderate coverage—sufficient for guidance but may lack depth of large-cap analysis.
Narrow estimate range signals strong analyst consensus and predictable business outlook.
Mixed signals—some positive indicators offset by concerns about growth or uncertainty.
Significant contraction projected—major business challenges or industry disruption likely.
Moderate coverage—sufficient for guidance but may lack depth of large-cap analysis.
Wide estimate range reveals significant forecast uncertainty and potential volatility.
Analyst skepticism evident—carefully evaluate risks before investment decisions.
Declining estimates with wide disagreement: Analysts projecting contraction without consensus signals significant business uncertainty—exercise caution.
Flat growth suggests market maturity or near-term challenges offsetting expansion efforts.
Limited coverage may indicate reduced institutional interest or information availability.
Wide estimate range reveals significant forecast uncertainty and potential volatility.
Analyst skepticism evident—carefully evaluate risks before investment decisions.
High forecast uncertainty: Wide estimate range indicates analysts struggling to predict outcomes—suggests elevated risk and potential volatility.
Strong growth expectations signal robust business momentum and market opportunity expansion.
Moderate coverage—sufficient for guidance but may lack depth of large-cap analysis.
Narrow estimate range signals strong analyst consensus and predictable business outlook.
Positive analyst consensus with strong growth expectations and forecast confidence.
Strong growth expectations signal robust business momentum and market opportunity expansion.
Moderate coverage—sufficient for guidance but may lack depth of large-cap analysis.
Narrow estimate range signals strong analyst consensus and predictable business outlook.
Positive analyst consensus with strong growth expectations and forecast confidence.
Significant contraction projected—major business challenges or industry disruption likely.
Moderate coverage—sufficient for guidance but may lack depth of large-cap analysis.
Narrow estimate range signals strong analyst consensus and predictable business outlook.
Mixed signals—some positive indicators offset by concerns about growth or uncertainty.
During the last 12 months, insiders have purchased $87.65M and sold $732K worth of ARTV shares, resulting in $86.92M of net buying activity.
7.6M
87.50M
53.0K
477.77K
+87.0M
+$87.02M
0
0.00
3.2K
19.12K
-19K
-$19K
0
0.00
31.9K
174.52K
-175K
-$175K
96.3K
154.96K
21.9K
60.25K
+95K
+$95K
Ra Capital Management, L.P.
Director, 10 Percent Owner:
$75.02M
Gc Corp.
10 Percent Owner
$12.50M
Daniels Brian
Director
$22K
Moore Alison
Director
$22K
Baker Daniel G.
Director
$22K
Aslan Fred
Director, Officer: Chief Executive Officer
$450K
Bush Jennifer
Officer: Coo, Clo, Compliance Officer
$97K
Horan Christopher
Officer: Chief Tech Operations Officer
$73K
Banerjee Subhashis
Officer: Chief Medical Officer
$63K
Raymon Heather
Officer: Svp, Research And Development
$32K
Strong bullish signal with $86.92M net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Exceptional buy/sell ratio. Buying dramatically outweighs selling—one of the strongest possible insider signals.
Very strong recent buying momentum. Recent insider purchases significantly outpace sales, suggesting near-term optimism.
5 insider buyers and 5 sellers. Equal participation suggests mixed or neutral insider views.
Strong confluence of bullish signals: High buy/sell ratio, multiple insiders participating, and recent buying momentum all point to significant insider confidence. This level of coordinated buying often precedes positive developments.
Continue your ARTV research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.